Partner Content Partner Content CAR:T - Has biology outpaced the ability to deliver? Experts comment on manufacturing of CAR-T
Partner Content Partner Content Complex Co-Cultured Spheroids to Validate Tumour Models in M... Complex Co-Cultured Spheroids in Cancer Research
Partner Content Partner Content When science and biology combine – the outlook for ADCs in c... Antibody Drug Conjugates (ADCs) are treatments formed by the conjugation of monoclonal antibodies and cytotoxic agents.
Partner Content Partner Content The first patient to be injected with an RNA based anti-canc... RNA Therapeutics
Partner Content Partner Content Oncology – the current landscape and what it means for the f... The WHO reports that in 2015, cancer was the second highest cause of death globally – responsible for 8.8 million fatalities, yet we are at a point in time where the speed of advancement in underst
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
